AlphaCore Capital’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

AlphaCore Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.16M	Buy	+29,355	New	+$1.05M	0.02%	476

Other funds holding TEVA

Harel Insurance Investments & Financial Services Ramat Gan, Israel $21.3B AUM 44.31% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Y.D. More Investments Ramat Gan, Israel $3.47B AUM 82.09% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Sound Shore Management Greenwich, Connecticut $3.2B AUM 19.02% 1-Year Est. Return

Todd Asset Management Louisville, Kentucky $5.51B AUM 33.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

AlphaCore Capital's TEVA Position: Q3 2026 in Review

AlphaCore Capital opened a new position in Teva Pharmaceutical Industries Limited (TEVA) in Q3 2026: 29,355 shares worth $1.16M. The stake represents 0.02% of the portfolio and ranks #476 among its holdings.

261 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

AlphaCore Capital held 29,355 shares of Teva Pharmaceutical Industries Limited worth $1.16M as of Q3 2026.
Teva Pharmaceutical Industries Limited was a new AlphaCore Capital position in Q3 2026.
Teva Pharmaceutical Industries Limited made up 0.02% of AlphaCore Capital's portfolio in Q3 2026, its #476 holding.
261 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.